Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Nirmatrelvir (PF-07321332) is a new oral antiviral drug developed by Pfizer. Nirmatrelvir is a major bioavailable oral SARS-CoV-2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off-target and in vivo...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant, and selective inhibitor of mutant IDH1. Olutasidenib was designed to reduce R-2-HG
and revert pathologic epigenetic modifications that impair cellular differentiation to...
Class (Stereo):
CHEMICAL (ACHIRAL)
Mitapivat (AG-348; PKM2 activator 1020) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte py...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Mavacamten (Camzyos™; MYK-461) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfun...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections. It inhibits cytochrome P450 (CYP) 51, thereby affecting the formation and integrity of the fungal ce...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Fosdenopterin (NulibryTM) is a synthetic cyclic pyranopterin monophosphate that is being developed by Origin Biosciences (a subsidiary of BridgeBio Pharma) for the treatment of molybdenum cofactor deficiency (MoCD) type A. Patients with MoCD Type A h...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. Sotorasib is an inhibitor of KRASG12C, a tumor...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Risdiplam (Evrysdi™) is an orally administered, survival motor neuron 2 (SMN2)-directed RNA splicing modifier being developed by Roche, PTC Therapeutics Inc and the SMA Foundation for the treatment of the spinal muscular atrophy. The small molecule i...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Pralsetinib (GAVRETO™, Blueprint Medicines Corporation) is an orally-administered, next-generation, small-molecule selective rearranged during transfection (RET) inhibitor being developed for the treatment of various solid tumours. RET is a well desc...
Class (Stereo):
CHEMICAL (ACHIRAL)
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.